Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer

Código QR

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer

Abstract Despite their recognised role in HER2-positive (HER2+) breast cancer (BC), the composition, localisation and functional orientation of immune cells within tumour microenvironment, as well as its dynamics during anti-HER2 treatment, is largely unknown. We here investigate changes in tumour-i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	G. Griguolo, G. Serna, T. Pascual, R. Fasani, X. Guardia, N. Chic, L. Paré, S. Pernas, M. Muñoz, M. Oliveira, M. Vidal, A. Llombart-Cussac, J. Cortés, P. Galván, B. Bermejo, N. Martínez, R. López, S. Morales, I. Garau, L. Manso, J. Alarcón, E. Martínez, P. Villagrasa, A. Prat, P. Nuciforo
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c2515a92ad4548f9831b897df5db6552
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
por: Fara Brasó-Maristany, et al.
Publicado: (2020)

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial
por: Tomás Pascual, et al.
Publicado: (2021)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani P, et al.
Publicado: (2015)

Current neoadjuvant treatment options for HER2 positive breast cancer
por: Abdel-Razeq H, et al.
Publicado: (2011)

The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers
por: Leticia De Mattos-Arruda, et al.
Publicado: (2021)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Avisek Majumder, et al.
Publicado: (2021)

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Francesco Schettini, et al.
Publicado: (2021)

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
por: Stenehjem DD, et al.
Publicado: (2014)

Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
por: Jennifer L. Caswell-Jin, et al.
Publicado: (2019)

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
por: Gaia Griguolo, et al.
Publicado: (2021)

Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
por: Jennifer L. Caswell-Jin, et al.
Publicado: (2019)

Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
por: Nindo B. Punturi, et al.
Publicado: (2021)

Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis
por: Yuefeng Wang, et al.
Publicado: (2017)

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
por: Amy S. Clark, et al.
Publicado: (2021)

Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
por: Ho Hyun Ryu, et al.
Publicado: (2021)

Pathological Complete Response to Neoadjuvant Chemotherapy in a Patient with HER2-Positive Squamous Cell Carcinoma of the Breast
por: Yuki Usui, et al.
Publicado: (2021)

Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
por: Yi Ding, et al.
Publicado: (2018)

Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.
por: Patrizia Nanni, et al.
Publicado: (2013)

Utility of Serum HER-2/ neu in Prediction of Tissue HER-2 /neu Status of Primary Breast Cancer
por: Maral Mokhtari, et al.
Publicado: (2021)

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
por: Alison E. Smith, et al.
Publicado: (2021)

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
por: Laura Pizzuti, et al.
Publicado: (2021)

Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer
por: Yunhua Liu, et al.
Publicado: (2018)

Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression
por: Veronica Giusti, et al.
Publicado: (2021)

Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.
por: David Lesniak, et al.
Publicado: (2013)

Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
por: Diana B. Peckys, et al.
Publicado: (2021)

HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer.
por: Merel Gijsen, et al.
Publicado: (2010)

Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab
por: Lize Wang, et al.
Publicado: (2021)

Targeted delivery of doxorubicin to HER2 positive tumor models
por: Gomari H, et al.
Publicado: (2019)

Remembering Sally Engle Merry: Her scholarship and her legacy
por: Anne Griffiths
Publicado: (2021)

Role of pertuzumab in the treatment of HER2-positive breast cancer
por: Hubalek M, et al.
Publicado: (2012)

Towards integration of 64Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer
por: Angela M. Jarrett, et al.
Publicado: (2020)

HER2 breast cancer therapies: a review
por: Conleth G Murphy, et al.
Publicado: (2009)

Bevacizumab in the treatment of HER2-negative breast cancer
por: Vito Lorusso
Publicado: (2008)

Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancer
por: Federica Miglietta, et al.
Publicado: (2021)

Targeted Delivery Of Doxorubicin To HER2 Positive Tumor Models [Corrigendum]
por: Gomari H, et al.
Publicado: (2019)

The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.
por: Angelo Gámez-Pozo, et al.
Publicado: (2014)

SORLA regulates endosomal trafficking and oncogenic fitness of HER2
por: Mika Pietilä, et al.
Publicado: (2019)

Contextual reprogramming of CAR-T cells for treatment of HER2+ cancers
por: Zhifen Yang, et al.
Publicado: (2021)

Copolymer micelles function as pH-responsive nanocarriers to enhance the cytotoxicity of a HER2 aptamer in HER2-positive breast cancer cells
por: Shen Y, et al.
Publicado: (2018)

Pathological Complete Response with Neoadjuvant Trastuzumab Combined with Chemotherapy in HER2 Positive Breast Cancer: A Single Institution Retrospective Analysis from Vietnam
por: Phung HT, et al.
Publicado: (2020)